أستراليا - الإنجليزية - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - alendronate sodium -

أستراليا - الإنجليزية - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - alendronate sodium -

أستراليا - الإنجليزية - Department of Health (Therapeutic Goods Administration)

generic health pty ltd - alendronate sodium -

أستراليا - الإنجليزية - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - alendronate sodium, quantity: 91.35 mg (equivalent: alendronic acid, qty 70 mg) - tablet, film coated - excipient ingredients: microcrystalline cellulose; croscarmellose sodium; colloidal anhydrous silica; macrogol 8000; carrageenan; magnesium stearate - treatment of osteoporosis, including glucocorticoid induced osteoporosis. osteoporosis must be confirmed by the finding of low bone mass of at least two standard deviations below the gender specific mean for young adults, or by the presence of osteoporotic fracture.

الولايات المتحدة - الإنجليزية - NLM (National Library of Medicine)

physicians total care, inc. - alendronate sodium (unii: 2uy4m2u3ra) (alendronic acid - unii:x1j18r4w8p) - alendronate sodium 5 mg - fosamax is indicated for: - treatment and prevention of osteoporosis in postmenopausal women for the treatment of osteoporosis, fosamax increases bone mass and reduces the incidence of fractures, including those of the hip and spine (vertebral compression fractures). osteoporosis may be confirmed by the finding of low bone mass (for example, at least 2 standard deviations below the premenopausal mean) or by the presence or history of osteoporotic fracture. (see clinical pharmacology, pharmacodynamics.) for the prevention of osteoporosis, fosamax may be considered in postmenopausal women who are at risk of developing osteoporosis and for whom the desired clinical outcome is to maintain bone mass and to reduce the risk of future fracture. bone loss is particularly rapid in postmenopausal women younger than age 60. risk factors often associated with the development of postmenopausal osteoporosis include early menopause; moderately low bone mass (for example, at least 1 standard deviatio

الولايات المتحدة - الإنجليزية - NLM (National Library of Medicine)

a-s medication solutions - alendronate sodium (unii: 2uy4m2u3ra) (alendronic acid - unii:x1j18r4w8p) - alendronate sodium tablets, usp are indicated for the treatment of osteoporosis in postmenopausal women. in postmenopausal women, alendronate sodium tablets, usp increase bone mass and reduces the incidence of fractures, including those of the hip and spine (vertebral compression fractures). [see clinical studies (14.1).] alendronate sodium tablets, usp are indicated for the prevention of postmenopausal osteoporosis [see clinical studies (14.2)] . alendronate sodium tablets, usp are indicated for treatment to increase bone mass in men with osteoporosis [see clinical studies (14.3)] . alendronate sodium tablets, usp are indicated for the treatment of glucocorticoid-induced osteoporosis in men and women receiving glucocorticoids in a daily dosage equivalent to 7.5 mg or greater of prednisone and who have low bone mineral density [see clinical studies (14.4)] . alendronate sodium tablets, usp are indicated for the treatment of paget's disease of bone in men and women. treatment is indicated in patients with page

الولايات المتحدة - الإنجليزية - NLM (National Library of Medicine)

bluebay shandong co.,ltd - alendronate sodium (unii: 2uy4m2u3ra) (alendronate sodium - unii:2uy4m2u3ra) -

الولايات المتحدة - الإنجليزية - NLM (National Library of Medicine)

bluebay shandong co.,ltd - alendronate sodium (unii: 2uy4m2u3ra) (alendronate sodium - unii:2uy4m2u3ra) -

أستراليا - الإنجليزية - Department of Health (Therapeutic Goods Administration)

apotex pty ltd - alendronate sodium,colecalciferol -

أستراليا - الإنجليزية - Department of Health (Therapeutic Goods Administration)

apotex pty ltd - alendronate sodium,colecalciferol -